Nephrology Times
Advertisement
Sarah Tolson reviews how changes to reimbursement for phosphate binders have affected dialysis programs.
A study assessed whether proton pump inhibitor use accelerated CKD progression and acute kidney injury risk.
Dr. Pranav Garimella, CMO of the American Kidney Fund, discussed AMKD awareness and the importance of APOL1 gene variants.
A study examined whether treatment of in-hospital BP elevations increases the risk of AKI and other adverse outcomes.
Researchers assessed the potential association between serum uric acid levels and CV events after kidney transplantation.
A study examined dosing practices and effectiveness of the urate-lowering drug allopurinol.
Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide.
KDIGO has issued its first updated guideline on the management of nephrotic syndrome in children since 2021.
Joel Topf spoke with Mini Michael about the ILLUMINATE-B study of lumasiran for PH1 in infants and young children.
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Joel Topf spoke with dietitian Melanie Betz about potassium, oxalate, and other renal nutrition concerns.
Joel Topf spoke with Areef Ishani about kidney stone outcomes from the Diuretic Comparison Project, a study of US veterans.
Joel Topf spoke to Seldin Award winner Roger Rodby at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke with Kathleen Liu about acute kidney injury and other topics ahead of her Massry lecture at SCM25.
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25.
Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS.
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.